Impact of High Lymph Node Burden on Brain Metastases in Patients Who Achieved Pathological Complete Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Cancer Res Treat · 2026 · PMC13382567 · PMID 40635453

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In terms of HER2-targeted therapy, trastuzumab was administered as a single agent or in combination with pertuzumab (dual blockade), with an increasing trend toward dual therapy use in recent years.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.